LOKAJ, Petr, Jindřich ŠPINAR, Lenka ŠPINAROVÁ, Filip MALEK, Ondřej LUDKA, Jan KREJČÍ, Petr OSTADAL, Dagmar VONDRAKOVA, Karel LÁBR, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Marie MIKLÍKOVÁ, Kateřina HELÁNOVÁ, Ilona PARENICOVA, Vladimír JAKUBO, Klára BENEŠOVÁ, Roman MIKLIK, Jiří JARKOVSKÝ, Tomáš ONDRÚŠ and Jiří PAŘENICA. Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction. Plos one. San Francisco: Public Library Science, 2021, vol. 16, No 7, p. 1-14. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0255271.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction
Authors LOKAJ, Petr (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Filip MALEK (203 Czech Republic), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Petr OSTADAL (203 Czech Republic), Dagmar VONDRAKOVA (203 Czech Republic), Karel LÁBR (203 Czech Republic, belonging to the institution), Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Marie MIKLÍKOVÁ (203 Czech Republic, belonging to the institution), Kateřina HELÁNOVÁ (203 Czech Republic, belonging to the institution), Ilona PARENICOVA (203 Czech Republic), Vladimír JAKUBO (703 Slovakia, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Roman MIKLIK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Tomáš ONDRÚŠ (703 Slovakia, guarantor, belonging to the institution) and Jiří PAŘENICA (203 Czech Republic, belonging to the institution).
Edition Plos one, San Francisco, Public Library Science, 2021, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10700 1.7 Other natural sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.752
RIV identification code RIV/00216224:14110/21:00122391
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0255271
UT WoS 000685248600043
Keywords in English high-sensitivity cardiac troponin I; heart failure patients; ejection fraction
Tags 14110115, 14110211, 14110518, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/9/2021 09:12.
Abstract
Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica(R), Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF < 40%) and HF with mid-range EF (HFmrEF) (LVEF 40%-49%). Methods and results A total of 520 patients with HFrEF and HFmrEF were enrolled in this study. Two-year all-cause mortality, heart transplantation, and/or left ventricular assist device implantation were defined as the primary endpoints (EP). A logistic regression analysis was used for the identification of predictors and development of multivariable models. The EP occurred in 14% of the patients, and these patients had higher NT-proBNP (1,950 vs. 518 ng/l; p < 0.001) and hs-cTnI (34 vs. 17 ng/l, p < 0.001) levels. C-statistics demonstrated that the optimal cut-off value for the hs-cTnI level was 17 ng/l (AUC 0.658, p < 0.001). Described by the AUC, the discriminatory power of the multivariable model (NYHA > II, NT-proBNP, hs-cTnI and urea) was 0.823 (p < 0.001). Including heart failure hospitalization as the component of the combined secondary endpoint leads to a diminished predictive power of increased hs-cTnI. Conclusion hs-cTnI levels >= 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF. Determining a patient's hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.
PrintDisplayed: 15/7/2024 01:29